[In symptomatic, nonhospitalized unvaccinated adults with mild to moderate COVID-19 at risk for progression to severe disease, does nirmatrelvir/ritonavir decrease the risk of COVID-19-related hospitalization or all-cause mortality while being safe?]

Rev Med Interne. 2022 Apr;43(4):270-271. doi: 10.1016/j.revmed.2022.02.008. Epub 2022 Feb 28.
[Article in French]
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • COVID-19* / drug therapy
  • Hospitalization
  • Humans
  • Ritonavir / adverse effects
  • SARS-CoV-2


  • Antiviral Agents
  • Ritonavir

Supplementary concepts

  • COVID-19 drug treatment